3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
18
Neoplasm Metastasis
2
Bulbo-Spinal Atrophy, X-Linked
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Melanoma
1
Esophageal Squamous Cell Carcinoma
1
Disease
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Bites and Stings
1
Advanced Solid Tumor
1
Adenocarcinoma
1
Interventions
enzalutamide
4
Docetaxel
2
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
abiraterone
1
Prednisone
1
PF06821497
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
abiraterone
×
Clear all
NCT07287150
2026-05-06
InavoPC
Hoffmann-La Roche
Phase 2
Recruiting
100 enrolled